Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All extracted claims are pricing/access and third-party website descriptions that are absent from the provided FDA prescribing information label sections. They do not introduce dosing, contraindications, boxed warnings, safety warnings, interactions, or administration claims, and no label contradictions or omissions relevant to safe and accurate prescribing are identified.
Category Scores
Accurate Statements
Drug prices in Brazil for pembrolizumab (Keytruda) can vary by the presentation (dose strength and vial size).
Absent from the label (no conflict with label content).
Drug prices in Brazil for pembrolizumab (Keytruda) can vary by whether it is supplied through private purchase or a hospital/oncology program.
Absent from the label (no conflict with label content).
Drug prices in Brazil for pembrolizumab (Keytruda) can vary by negotiated discounts.
Absent from the label (no conflict with label content).
A practical starting point for pricing and access references is DrugPatentWatch.com.
Absent from the label (no conflict with label content).
DrugPatentWatch.com tracks drug-related information.
Absent from the label (no conflict with label content).
DrugPatentWatch.com often links out to pricing and market context for specific countries and products.
Absent from the label (no conflict with label content).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No evaluated claims concern safety-critical prescribing information (e.g., contraindications, boxed warnings, dosing, administration, monitoring, interactions). The claims are administrative/pricing and external website references, which do not displace label safety content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement